The TMED4 antibody targets the Transmembrane Emp24 Domain-Containing Protein 4 (TMED4), a member of the transmembrane p24 trafficking protein family. TMED4. also known as p27 or TMP21. plays a critical role in vesicular protein transport between the endoplasmic reticulum (ER) and Golgi apparatus. It facilitates cargo sorting and the formation of COPII-coated vesicles, which are essential for maintaining cellular secretion pathways. TMED4 is implicated in regulating the trafficking of secretory proteins, including amyloid precursor protein (APP), linking it to neurodegenerative diseases like Alzheimer's.
Antibodies against TMED4 are widely used to study its expression, localization, and interaction partners in cellular models. They enable detection via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Research utilizing TMED4 antibodies has shed light on its role in pathological processes, including cancer progression, inflammation, and neurodegeneration. For example, altered TMED4 expression has been observed in certain tumors, suggesting its potential as a biomarker or therapeutic target.
These antibodies are crucial tools for exploring TMED4's molecular functions and its involvement in diseases, aiding both basic research and clinical investigations.